Management of heparin-induced thrombocytopenia with factor xa inhibitors: A systematic review

Q4 Medicine Thrombosis Update Pub Date : 2024-07-24 DOI:10.1016/j.tru.2024.100185
Colton Jones , Abiodun Idowu , Elvis Obomanu , Raymond Smith , Karecia Byfield , Avinash Ramkissoon , Kevin Bryan Lo , Ryan Mayo
{"title":"Management of heparin-induced thrombocytopenia with factor xa inhibitors: A systematic review","authors":"Colton Jones ,&nbsp;Abiodun Idowu ,&nbsp;Elvis Obomanu ,&nbsp;Raymond Smith ,&nbsp;Karecia Byfield ,&nbsp;Avinash Ramkissoon ,&nbsp;Kevin Bryan Lo ,&nbsp;Ryan Mayo","doi":"10.1016/j.tru.2024.100185","DOIUrl":null,"url":null,"abstract":"<div><p>Heparin-induced thrombocytopenia (HIT) is a rare but severe prothrombotic disorder that develops in patients exposed to heparin products. Diagnosis is associated with significant morbidity and mortality. The mainstay of treatment for HIT involves discontinuing all heparin products and administering non-heparin anticoagulants. Since the publication of the American Society of Hematology (ASH) guidelines in 2018, factor Xa inhibitors have become an attractive alternative. We systematically reviewed the literature to determine the efficacy and safety of factor Xa inhibitors in managing HIT. We included any case series, retrospective, or prospective study that evaluated the efficacy of factor Xa inhibitors. We searched PubMed, Ovid, Embase, Cochrane Central Register of Controlled Trials, and Google Scholar from inception to September 2023. Three reviewers independently reviewed titles, abstracts, and full-text articles to determine eligibility using prespecified inclusion and exclusion criteria. Disagreements were resolved by discussion and consensus. Nine hundred sixty-four articles were screened against title and abstract, and 75 studies were selected for full-text review. Fifteen studies eventually met the inclusion criteria. Two hundred eighty-five patients across 15 studies were treated with factor Xa inhibitor. Across all study arms combined, HIT thrombosis-associated mortality was 0 % (n = 0), recurrent thrombosis was 4.56 % (n = 13), and major bleeding was 2.80 % (n = 8). Factor Xa inhibitors showed positive outcomes in HIT in terms of both safety and efficacy. Major limitation of this review is that the studies included are primarily retrospective and, thus, are subject to inherent limitations of observational study design. More randomized controlled trials (RCT) or prospective studies examining non-inferiority or superiority of transitioning to direct oral anticoagulant (DOAC) vs primary treatment with DOAC are needed.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572724000270/pdfft?md5=237ceb7c77231c44b9e5334492078af2&pid=1-s2.0-S2666572724000270-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572724000270","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Heparin-induced thrombocytopenia (HIT) is a rare but severe prothrombotic disorder that develops in patients exposed to heparin products. Diagnosis is associated with significant morbidity and mortality. The mainstay of treatment for HIT involves discontinuing all heparin products and administering non-heparin anticoagulants. Since the publication of the American Society of Hematology (ASH) guidelines in 2018, factor Xa inhibitors have become an attractive alternative. We systematically reviewed the literature to determine the efficacy and safety of factor Xa inhibitors in managing HIT. We included any case series, retrospective, or prospective study that evaluated the efficacy of factor Xa inhibitors. We searched PubMed, Ovid, Embase, Cochrane Central Register of Controlled Trials, and Google Scholar from inception to September 2023. Three reviewers independently reviewed titles, abstracts, and full-text articles to determine eligibility using prespecified inclusion and exclusion criteria. Disagreements were resolved by discussion and consensus. Nine hundred sixty-four articles were screened against title and abstract, and 75 studies were selected for full-text review. Fifteen studies eventually met the inclusion criteria. Two hundred eighty-five patients across 15 studies were treated with factor Xa inhibitor. Across all study arms combined, HIT thrombosis-associated mortality was 0 % (n = 0), recurrent thrombosis was 4.56 % (n = 13), and major bleeding was 2.80 % (n = 8). Factor Xa inhibitors showed positive outcomes in HIT in terms of both safety and efficacy. Major limitation of this review is that the studies included are primarily retrospective and, thus, are subject to inherent limitations of observational study design. More randomized controlled trials (RCT) or prospective studies examining non-inferiority or superiority of transitioning to direct oral anticoagulant (DOAC) vs primary treatment with DOAC are needed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用 Xa 因子抑制剂治疗肝素诱发的血小板减少症:系统回顾
肝素诱导的血小板减少症(HIT)是一种罕见但严重的血栓前疾病,发生在接触肝素产品的患者身上。确诊后会导致严重的发病率和死亡率。治疗 HIT 的主要方法是停用所有肝素产品并使用非肝素抗凝剂。自2018年美国血液学会(ASH)指南发布以来,Xa因子抑制剂已成为一种有吸引力的替代疗法。我们系统地回顾了相关文献,以确定 Xa 因子抑制剂治疗 HIT 的有效性和安全性。我们纳入了所有评估 Xa 因子抑制剂疗效的系列病例、回顾性或前瞻性研究。我们检索了从开始到 2023 年 9 月的 PubMed、Ovid、Embase、Cochrane Central Register of Controlled Trials 和 Google Scholar。三位审稿人分别独立审阅了文章的标题、摘要和全文,并根据预先规定的纳入和排除标准确定是否符合条件。如有分歧,则通过讨论和协商一致的方式解决。根据标题和摘要筛选了 964 篇文章,并选择了 75 项研究进行全文审阅。最终有 15 项研究符合纳入标准。15 项研究中有 285 名患者接受了 Xa 因子抑制剂治疗。在所有研究臂中,HIT血栓相关死亡率为0%(n = 0),复发性血栓为4.56%(n = 13),大出血为2.80%(n = 8)。因子 Xa 抑制剂在安全性和有效性方面对 HIT 都有积极的疗效。本综述的主要局限性在于所纳入的研究主要是回顾性研究,因此受到观察性研究设计的固有局限性的影响。需要进行更多的随机对照试验(RCT)或前瞻性研究,考察过渡到直接口服抗凝剂(DOAC)与使用 DOAC 进行初始治疗的非劣效性或优越性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thrombosis Update
Thrombosis Update Medicine-Hematology
CiteScore
1.90
自引率
0.00%
发文量
33
审稿时长
86 days
期刊最新文献
Tissue factor (F3) gene variants and thrombotic risk among middle-aged and older adults: A population-based cohort study Catheter – related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO) Usability study of the qLabs® FIB: A new point-of-care system for functional fibrinogen testing Nitrous oxide and VTE – no laughing matter Practical model for implementation of cancer-associated thrombosis prevention in the outpatient setting
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1